To stay innovative and competitive as a leading provider in advanced drug delivery devices such as auto injectors and pen injectors, SHL continuously invests in developing new pragmatic products that reflect industry trends and end-user needs.
The most recent examples include the higher volume auto injector, Molly 2.25, as well as Molly C, a connected device that responds to the definitive trend amid widespread use of the internet.
Both devices are based on the well-known Molly auto injector, a two-step device that revolutionised the industry with its simplicity, ease-of-use and compactness.
In this podcast, executive director of Business Development in Europe, Nick Heaton, talks about the major drivers of growing demands in Europe for advanced drug delivery devices, and measures taken to enhance the company’s relationship with patients and biopharmaceutical companies.
Heaton also addresses challenges faced when launching a new product and explains the main difference between a preconfigured programme and development programme offered by SHL, as well each programme’s respective opportunities and advantages.
The podcast is available on SHL’s website.